Risk Assessment and Meningococcal A Conjugate Vaccine Introduction in Africa: The District Prioritization Tool

Autor: Katya Fernandez, Clement Lingani, Mamoudou Harouna Djingarey, Stéphane Hugonnet, William Perea, Laurence Cibrelus

Publikováno v: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Predominantly caused by Neisseria meningitidis group A (NmA), recurrent epidemics of meningococcal meningitis have placed a heavy toll on countries of the African “meningitis belt” [1–7]. Until recently, the combination of early detection, case

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::189ef31a10260ecda5086b6b805b1add
https://doi.org/10.1093/cid/civ671

Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013

Autor: Patrick L.F. Zuber, Bartholomew Dicky Akanmori, Samba O. Sow, Téné M. Yaméogo, Modibo Keita, Mamoudou Harouna Djingarey, Simonetta Viviani, Nehemie Mbakuliyemo, Kirsten S. Vannice, Fabien Diomandé, Marie-Pierre Preziosi, Claude-Roger Ouandaogo

Publikováno v: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

A group A meningococcal conjugate vaccine, PsA-TT, was developed by the Meningitis Vaccine Project and the Serum Institute of India, Ltd (SIIL). Clinical trials conducted among approximately 10 000 persons aged 1–29 years, in India and in Africa, c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39de76e27090cc449d824514e23aedc4
http://europepmc.org/articles/PMC4639501

Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014

Autor: Clement Lingani, Mamoudou Harouna Djingarey, Denis Kandolo, Ryan T. Novak, William Perea, Rodrigue Barry, Fabien Diomandé, Carol Tevi-Benissan, Florence Shirehwa, Marie-Pierre Preziosi, F. Marc LaForce

Publikováno v: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Background. A group A meningococcal conjugate vaccine (PsA-TT) was developed specifically for the African “meningitis belt” and was prequalified by the World Health Organization (WHO) in June 2010. The vaccine was first used widely in Burkina Fas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8b37d1b5022fb2597f06bebb7cb9203
https://pubmed.ncbi.nlm.nih.gov/26553672

Public Health Impact After the Introduction of PsA-TT: The First 4 Years

Autor: Kadidja Gamougam, Nehemie Mbakuliyemo, Denis Kandolo, Nancy E. Messonnier, James M. Stuart, F. Marc LaForce, Jean-Marc Collard, Paul A. Kristiansen, Ryan T. Novak, Doumagoum M. Daugla, William Perea, Brian Greenwood, Fabien Diomandé, Carol Tevi-Benissan, Mamoudou Harouna Djingarey, Marie-Pierre Preziosi, O. Walker, Thomas A. Clark, Dominique A. Caugant, Leonard W. Mayer

Publikováno v: Clinical Infectious Diseases
Clinical Infectious Diseases, Oxford University Press (OUP), 2015, 61 (suppl_5), pp.S467-S472. ⟨10.1093/cid/civ499⟩
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

International audience; Background. During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010–2011 and its rollout from 2011 to 2013, >150 million eligible people, representing 12 hyperendemic meningitis countries, have been

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e0f832aac82940364ba93875da5c003
https://researchonline.lshtm.ac.uk/id/eprint/2551457/1/civ499.PMC4639484.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.